Results 51 to 60 of about 66,588 (284)

Clinical and biochemical response to neridronate treatment in a patient with osteoporosis-pseudoglioma syndrome (OPPG) [PDF]

open access: yes, 2017
Osteoporosis-pseudoglioma syndrome (OPPG) is a rare autosomal recessive syndrome characterized by juvenile-onset osteoporosis and ocular abnormalities due to a low-density lipoprotein receptor-related protein 5 (LRP5) gene mutation.
Celli, L   +7 more
core   +1 more source

Engineering Extracellular Vesicle Production Through Magnetic Ion Channel Activation for Bone Regeneration

open access: yesAdvanced Healthcare Materials, EarlyView.
Magnetic Ion Channel Activation (MICA) enables remote stimulation of mechanosensitive ion channels using functionalised magnetic nanoparticles, enhancing extracellular vesicle (EV) biogenesis is pre‐osteoblasts. MICA desrived EVs exhibit typical nano‐vesicular characteristics but display superior pro‐osteogeneic activity, promoting mesenchymal stem ...
Afeesh Rajan Unnithan   +9 more
wiley   +1 more source

Prevention of osteoporotic refractures in regional Australia [PDF]

open access: yes, 2017
Objective: Clinical guidelines recommend that patients who sustain a minimal trauma fracture (MTF) should receive a bone mineral density (BMD) scan and bisphosphonate (or equivalent) therapy if diagnosed with osteoporosis.
Davidson, E   +4 more
core   +2 more sources

Bone Healing Around Implants in Normal and Medically Compromised Conditions: Osteoporosis and Diabetes

open access: yesAdvanced Healthcare Materials, EarlyView.
xx xx. ABSTRACT Osseointegration of orthopedic and dental implants is influenced by local and systemic factors, including their physicochemical surface properties and the patient's overall health status. Titanium and its alloys have been a longstanding standard for bone implants due to their innate biocompatibility and mechanical properties.
Dainelys Guadarrama Bello   +2 more
wiley   +1 more source

Bisphosphonates in Total Joint Arthroplasty: A Review of Their Use and Complications

open access: yesArthroplasty Today, 2022
Background: Considerable interest has been expressed in the use of bisphosphonates to treat periprosthetic osteoporosis with the clinical goals of reducing periprosthetic fractures and prolonging implant survival.
Christopher L. McDonald, MD   +5 more
doaj   +1 more source

Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects

open access: yesAdvanced Materials, EarlyView.
Mesoporous silica nanoparticles offer unique properties like high surface area, tunable pores, and functionalization. They excel in drug delivery, tissue engineering, and stimuli‐responsive therapies, enabling targeted and controlled treatments. With roles in cancer therapy and diagnostics, their clinical translation requires addressing challenges in ...
Miguel Manzano, María Vallet‐Regí
wiley   +1 more source

Coping with complexity: working beyond the guidelines for patients with multimorbidities [PDF]

open access: yes, 2015
Primary care physicians believe they are delivering evidence-based care, understanding that adherence to evidence-based clinical guidelines results in tangible benefits in the populations for which they were developed.
Treadwell, Julian
core   +3 more sources

Engineering Osteoimmune Responses with Functionalized Orthopedic Implants for Post‐Operative Osteosarcoma Treatment

open access: yesAdvanced Science, EarlyView.
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong   +6 more
wiley   +1 more source

Biological evaluations of novel 2,3,3-Trisphosphonate in osteoclastic and osteoblastic activities [PDF]

open access: yes, 2017
Bisphosphonates (BPs) are the first line treatment for many bone diseases including hypercalcimia associated with bone malignancies. In this paper, we introduce a new analogue of bisphosphonate called the 2,3,3-Trisphosphonate (2,3,3-TriPP) that was ...
Boccaccini, Aldo R.   +4 more
core   +3 more sources

An Implantable Scaffold Sequentially Releasing STING Agonist and B7‐H3 Antibody for Bone Metastasis Immunotherapy

open access: yesAdvanced Science, EarlyView.
We developed an implantable dual‐drug depot using GelMA for bone metastasis treatment, co‐delivering MSA‐2 and αB7‐H3‐loaded CaCO3 microparticles. Sustained release from GelMA scaffold enables MSA‐2 to activate STING signaling and enhance T‐cell infiltration and activation, while sequentially released αB7‐H3 blocks MSA‐2‐induced B7‐H3 upregulation ...
Qijun Lin   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy